The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses.

[1]  D. Haines,et al.  Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. , 2010, Equine veterinary journal.

[2]  J. Daly,et al.  Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an 'American lineage' H3N8 virus. , 2004, Vaccine.

[3]  Y. Kawaoka,et al.  Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. , 2003, Vaccine.

[4]  J. Daly,et al.  Diagnostic methods applied to analysis of an outbreak of equine influenza in a riding school in which vaccine failure occurred. , 2003, Veterinary microbiology.

[5]  W. Stok,et al.  Improvement of the systemic prime/oral boost strategy for systemic and local responses. , 2003, Vaccine.

[6]  L. Hilgers,et al.  A Multiple Dose Immunisation Protocol Suitable For Edible Vaccines , 2001 .

[7]  M. Pearse,et al.  Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses. , 2001, Vaccine.

[8]  P. Ogra,et al.  Vaccination Strategies for Mucosal Immune Responses , 2001, Clinical Microbiology Reviews.

[9]  A. Cripps,et al.  Vaccines and mucosal immunisation. , 2001, Vaccine.

[10]  J. Mcghee,et al.  Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. , 2001, The Journal of infectious diseases.

[11]  B. Arulanandam,et al.  IgA Immunodeficiency Leads to Inadequate Th Cell Priming and Increased Susceptibility to Influenza Virus Infection , 2001, The Journal of Immunology.

[12]  M. Murtaugh,et al.  Mechanisms of vaccine adjuvanticity at mucosal surfaces , 2000, Animal Health Research Reviews.

[13]  Lihan K. Yan,et al.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. , 2000, The Journal of infectious diseases.

[14]  G. Dougan,et al.  Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. , 1999, Immunology today.

[15]  W. Gruber,et al.  Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. , 1999 .

[16]  D. Haines,et al.  Efficacy of a commercial vaccine for preventing disease caused by influenza virus infection in horses. , 1999, Journal of the American Veterinary Medical Association.

[17]  Y. Barenholz,et al.  A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. , 1999, Vaccine.

[18]  H. Carol,et al.  A mucosal IgA response, but no systemic antibody response, is evoked by intranasal immunisation of dogs with Echinococcus granulosus surface antigens iscoms. , 1998, Veterinary Immunology and Immunopathology.

[19]  A. Sheoran,et al.  Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination. , 1998, Vaccine.

[20]  Åkerblom,et al.  The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses , 1998, Clinical and experimental immunology.

[21]  I. Barr,et al.  ISCOMs and other saponin based adjuvants. , 1998, Advanced drug delivery reviews.

[22]  Z. Moldoveanu,et al.  CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. , 1998, Vaccine.

[23]  O’Hagan,et al.  Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses , 1998, Immunology.

[24]  E. Claassen,et al.  Immune responses and side effects of five different oil-based adjuvants in mice. , 1998, Veterinary immunology and immunopathology.

[25]  M. Villacrés-Eriksson,et al.  Intranasal immunization of mice with Echinococcus granulosus surface antigens Iscoms evokes a strong immune response, biased towards glucidic epitopes , 1997, Parasite immunology.

[26]  P. Kutzer,et al.  [Vaccination of pigeons against Salmonella infections]. , 1997, Berliner und Munchener tierarztliche Wochenschrift.

[27]  J. Cox,et al.  Adjuvants--a classification and review of their modes of action. , 1997, Vaccine.

[28]  D. Antczak,et al.  Summary report of the Second Equine Leucocyte Antigen Workshop. , 1996, Veterinary immunology and immunopathology.

[29]  A. Delmas,et al.  Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunization. , 1996, Vaccine.

[30]  J. R. Newton,et al.  Equine influenza in vaccinated horses , 1995, Veterinary Record.

[31]  D. O’hagan.  Novel Delivery Systems for Oral Vaccines , 1994 .

[32]  D. Hannant,et al.  Duration of protective efficacy of equine influenza immunostimulating complex/tetanus vaccines , 1994, Veterinary Record.

[33]  G. Gregoriadis,et al.  Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. , 1993, Vaccine.

[34]  C. Kaetzel,et al.  Intracellular neutralization of virus by immunoglobulin A antibodies. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Czerkinsky,et al.  Mucosal immunity: implications for vaccine development. , 1992, Immunobiology.

[36]  T. Nagamine,et al.  Cross‐protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules , 1991, European journal of immunology.

[37]  P. Small,et al.  Immunoglobulin A mediation of murine nasal anti-influenza virus immunity , 1991, Journal of Virology.

[38]  P. Small,et al.  Passive transfer of local immunity to influenza virus infection by IgA antibody. , 1991, Journal of immunology.

[39]  K. Lövgren,et al.  An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration , 1990, Clinical and experimental immunology.

[40]  T. Nagamine,et al.  Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. , 1990, Vaccine.

[41]  J. Mumford,et al.  Experimental infection of ponies with equine influenza (H3N8) viruses by intranasal inoculation or exposure to aerosols. , 1990, Equine veterinary journal.

[42]  B. Bokhout,et al.  Quantification of antigen-specific antibody-secreting cells in the small intestine and other lymphoid organs of mice after oral booster immunization. , 1989, Immunology.

[43]  B. Morein,et al.  Cellular Immune Responses in the Murine Lung to Local Immunization with Influenza A Virus Glycoproteins in Micelles and Immunostimulatory Complexes (Iscoms) , 1988, Scandinavian journal of immunology.

[44]  G. Schild,et al.  Protection against experimental infection with influenza virus A/equine/Miami/63 (H3N8) provided by inactivated whole virus vaccines containing homologous virus , 1988, Epidemiology and Infection.

[45]  K. Lövgren.  The Serum Antibody Response Distributed in Subclasses and Isotypes after Intranasal and Subcutaneous Immunization with Influenza Virus Immunostimulating Complexes , 1988, Scandinavian journal of immunology.

[46]  B. Murphy,et al.  Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus , 1986, Journal of clinical microbiology.

[47]  P. Wright,et al.  Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. , 1986, The Journal of infectious diseases.

[48]  A. Smithyman,et al.  The effects of oral and combined parenteral/oral immunization against an experimental Escherichia coli urinary tract infection in mice. , 1983, Clinical and experimental immunology.

[49]  J. Mumford,et al.  Studies with inactivated equine influenza vaccine: 1. Serological responses of ponies to graded doses of vaccine , 1983, Journal of Hygiene.

[50]  J. Bienenstock,et al.  Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. , 1979, Journal of immunology.

[51]  R. Sack,et al.  Immunity to experimental cholera. III. Enhanced duration of protection after sequential parenteral-oral administration of toxoid to dogs. , 1977, The Journal of infectious diseases.

[52]  A. Almeida,et al.  Nasal delivery of vaccines. , 1996, Journal of drug targeting.

[53]  R. F. Cook,et al.  Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. , 1994, Vaccine.

[54]  J. Wood,et al.  Establishing an acceptability threshold for equine influenza vaccines. , 1992, Developments in biological standardization.

[55]  J. Mcghee,et al.  The mucosal immune system: from fundamental concepts to vaccine development. , 1992, Vaccine.

[56]  B. Murphy,et al.  The systemic and mucosal immune response of humans to influenza A virus. , 1989, Current topics in microbiology and immunology.

[57]  S. Höglund,et al.  The ISCOM: an immunostimulating complex. , 1987, Immunology today.

[58]  F. Liew,et al.  Cross‐protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity , 1984, European journal of immunology.

[59]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.